NCT07173478View on ClinicalTrials.gov

A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Atopic Dermatitis (AD)
Interventions
DRUG

OPA-15406

1% foam, topical, twice daily, for 4 weeks

DRUG

Vehicle

vehicle, topical, twice daily, for 4 weeks

Trial Locations (1)

Unknown

Mita Dermatology Clinic, Tokyo

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

NCT07173478 - A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis | Biotech Hunter | Biotech Hunter